HIMS vs. HALO
HIMS (Hims & Hers Health, Inc.) and HALO (Halozyme Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — HIMS in Drug Manufacturers - Specialty & Generic, HALO in Biotechnology. Over the past 5 years, HIMS returned 25.12%/yr vs 8.86%/yr for HALO. At a 0.22 correlation, their price movements are largely independent.
Performance
HIMS vs. HALO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HIMS achieves a 1.51% return, which is significantly lower than HALO's 3.45% return.
HIMS
- 1D
- -1.73%
- 1M
- 38.78%
- YTD
- 1.51%
- 6M
- -5.29%
- 1Y
- -21.49%
- 3Y*
- 57.60%
- 5Y*
- 25.12%
- 10Y*
- —
HALO
- 1D
- 0.91%
- 1M
- 1.90%
- YTD
- 3.45%
- 6M
- 1.84%
- 1Y
- 31.86%
- 3Y*
- 26.81%
- 5Y*
- 8.86%
- 10Y*
- 23.49%
HIMS vs. HALO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
HIMS Hims & Hers Health, Inc. | 1.51% | 34.28% | 171.69% | 38.85% | -2.14% | -55.14% | 47.47% | 1.23% |
HALO Halozyme Therapeutics, Inc. | 3.45% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 7.52% |
Correlation
The correlation between HIMS and HALO is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Sep 13, 2019 | 0.22 |
The correlation between HIMS and HALO shifts across timeframes, from 0.14 (1 year) to 0.26 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
HIMS:
$7.53B
HALO:
$8.55B
HIMS:
-$0.05
HALO:
$2.87
HIMS:
3.41
HALO:
5.62
HIMS:
16.87
HALO:
38.95
HIMS:
$2.37B
HALO:
$1.51B
HIMS:
$1.70B
HALO:
$1.23B
HIMS:
$16.04M
HALO:
$980.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HIMS vs. HALO — Risk / Return Rank
HIMS
HALO
HIMS vs. HALO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Hims & Hers Health, Inc. (HIMS) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HIMS | HALO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.29 | ||
| Sortino ratioReturn per unit of downside risk | -1.29 | ||
| Omega ratioGain probability vs. loss probability | 1.03 | 1.19 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | -0.28 | 1.33 | -1.60 |
| Martin ratioReturn relative to average drawdown | -0.45 | 2.47 | -2.92 |
Loading charts...
Drawdowns
HIMS vs. HALO - Drawdown Comparison
The maximum HIMS drawdown since its inception was -87.29%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HIMS and HALO.
Loading charts...
Drawdown Indicators
| HIMS | HALO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.29% | -74.26% | -13.03% |
Max Drawdown (1Y)Largest decline over 1 year | -78.06% | -24.13% | -53.93% |
Max Drawdown (3Y)Largest decline over 3 years | -78.88% | -33.92% | -44.96% |
Max Drawdown (5Y)Largest decline over 5 years | -78.88% | -49.06% | -29.82% |
Max Drawdown (10Y)Largest decline over 10 years | — | -49.06% | — |
Current DrawdownCurrent decline from peak | -52.05% | -14.29% | -37.76% |
Average DrawdownAverage peak-to-trough decline | -43.26% | -31.86% | -11.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 48.15% | 12.92% | +35.23% |
Volatility
HIMS vs. HALO - Volatility Comparison
Hims & Hers Health, Inc. (HIMS) has a higher volatility of 23.50% compared to Halozyme Therapeutics, Inc. (HALO) at 8.95%. This indicates that HIMS's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HIMS | HALO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.50% | 8.95% | +14.55% |
Volatility (6M)Calculated over the trailing 6-month period | 69.23% | 24.08% | +45.15% |
Volatility (1Y)Calculated over the trailing 1-year period | 97.66% | 30.35% | +67.31% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 83.58% | 39.44% | +44.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 77.37% | 42.74% | +34.63% |
Dividends
HIMS vs. HALO - Dividend Comparison
Neither HIMS nor HALO has paid dividends to shareholders.
Financials
HIMS vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Hims & Hers Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HIMS vs. HALO - Profitability Comparison
HIMS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a gross profit of 396.79M and revenue of 608.10M. Therefore, the gross margin over that period was 65.3%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
HIMS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported an operating income of -78.32M and revenue of 608.10M, resulting in an operating margin of -12.9%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
HIMS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a net income of -92.12M and revenue of 608.10M, resulting in a net margin of -15.2%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
Frequently Asked Questions
HIMS and HALO have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HIMS has higher volatility (23.50%) compared to HALO (8.95%). In terms of maximum drawdown, HIMS dropped -87.29% vs HALO's -74.26%.
HALO currently has the higher Sharpe Ratio (1.05 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HIMS and HALO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer